Compare Sana Biotechnology Inc (SANA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs DENTSPLY SIRONA Inc — how do they compare? Sana Biotechnology Inc trades at $3.85 (market cap $1.13B), while DENTSPLY SIRONA Inc trades at $11.39 (market cap $2.31B). The key difference: DENTSPLY SIRONA Inc is far larger — about 2× Sana Biotechnology Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | XRAY | |
|---|---|---|
Market Cap | $1.13B | $2.31B |
Sector | Health | Health |
52-Week High | $5.92 | $14.68 |
52-Week Low | $2.68 | $9.64 |
Enterprise Value | $1.05B | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.
Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
